z-logo
Premium
Repeatability of bronchial responsiveness to mannitol dry powder in children with asthma
Author(s) -
Barben Juerg,
Roberts Mary,
Chew Nora,
Carlin John B.,
Robertson Colin F.
Publication year - 2003
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.10378
Subject(s) - medicine , repeatability , asthma , concordance , mannitol , geometric mean , concordance correlation coefficient , pediatrics , airway , dry powder inhaler , anesthesia , inhaler , statistics , chemistry , mathematics , organic chemistry
Our objective was to determine the repeatability of bronchial responsiveness to mannitol dry powder (MDP) as an objective marker of asthma in children. MDP challenge was performed in children with stable asthma at the same time of the day on two separate occasions within a week. The test was terminated after a 15% fall of forced expiratory volume in 1 sec (FEV 1 ) and the provocative dose to produce a 15% fall in FEV 1 (PD 15 ) were calculated. Seventeen children (aged 9–16 years) on inhaled corticosteroids (200–1,500 mcg) were studied. Mean baseline FEV 1 before the challenges were 95% (81–119) and 96% (74–121), respectively, with a standard deviation of differences of 5.2%. PD 15 values ranged from 7–387 mg, with a geometric mean of 38 mg for the first and 49 mg for the second test. Of the 17, all but two pairs of tests achieved a PD 15 within one dose of capsules. Four children had a negative challenge on two occasions. A high relative reliability was reflected by a concordance coefficient of 0.86. In conclusion, MDP is a convenient challenge which is easy to administer and is well‐tolerated by children. It is a highly reproducible test of airway responsiveness in children with moderate to severe persistent asthma on inhaled corticosteroids within 7 days under laboratory conditions. Pediatr Pulmonol. 2003; 36:490–494. © 2003 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here